100 related articles for article (PubMed ID: 20129368)
1. Extracorporeal LDL cholesterol elimination (25 years of experience in CZ).
Blaha M; Zadak Z; Blaha V; Andrys C; Havel E; Vyroubal P; Blazek M; Filip S; Lanska M; Maly J
Atheroscler Suppl; 2009 Dec; 10(5):17-20. PubMed ID: 20129368
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein apheresis in the treatment of dyslipidaemia - the Czech Republic experience.
Bláha V; Bláha M; Lánská M; Solichová D; Kujovská Krčmová L; Havel E; Vyroubal P; Zadák Z; Žák P; Sobotka L
Physiol Res; 2017 Apr; 66(Suppl 1):S91-S100. PubMed ID: 28379034
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia.
Blaha M; Cermanova M; Blaha V; Jarolim P; Andrys C; Blazek M; Maly J; Smolej L; Zajic J; Masin V; Zimova R; Rehacek V
Atherosclerosis; 2008 Mar; 197(1):264-70. PubMed ID: 17540382
[TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein levels and not mutation status predict intima-media thickness in familial hypercholesterolemia.
Fahed AC; Habib RH; Nemer GM; Azar ST; Andary RR; Arabi MT; Moubarak EM; Bitar FF; Haddad FF
Ann Vasc Surg; 2014 Feb; 28(2):421-6. PubMed ID: 24120234
[TBL] [Abstract][Full Text] [Related]
5. The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia.
Koga N
Ther Apher; 1997 Aug; 1(3):260-70. PubMed ID: 10225750
[TBL] [Abstract][Full Text] [Related]
6. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.
Yamamoto A; Harada-Shiba M; Endo M; Kusakabe N; Tanioka T; Kato H; Shoji T
Atherosclerosis; 2006 May; 186(1):126-31. PubMed ID: 16043185
[TBL] [Abstract][Full Text] [Related]
7. [Extracorporeal elimination of LDL-cholesterol in the treatment of hypercholesterolemia: indications and methods].
Bláha V; Havel E; Zadák Z; Pidrman V; Bláha M; Kalinová M
Vnitr Lek; 1995 Oct; 41(10):724-9. PubMed ID: 8578708
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy in homozygous familial hypercholesterolemia--Importance of LDL-apheresis.
Blaha M; Lanska M; Blaha V; Boudys L; Zak P
Atheroscler Suppl; 2015 May; 18():134-9. PubMed ID: 25936317
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of homozygous familial hypercholesterolemia with LDL-apheresis on a 4-year-old child].
Lefort B; Giraud C; Saulnier JP; Bott L; Gambert C; Sosner P; Hankard R
Arch Pediatr; 2009 Dec; 16(12):1554-8. PubMed ID: 19766469
[TBL] [Abstract][Full Text] [Related]
10. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia.
Thiery J; Seidel D
Transfus Sci; 1993 Jul; 14(3):249-59. PubMed ID: 10146336
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia.
Streicher J; Valent P; Schmidt H; Sengölge G; Wagner O; Strobl W; Hörl WH; Derfler K
J Investig Med; 1999 Sep; 47(8):378-87. PubMed ID: 10510590
[TBL] [Abstract][Full Text] [Related]
12. [LDL apheresis in the treatment of hyperlipoproteinemia].
Ishikawa K
Nihon Rinsho; 1994 Dec; 52(12):3298-302. PubMed ID: 7853726
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients.
Koga N; Watanabe K; Kurashige Y; Sato T; Hiroki T
J Intern Med; 1999 Jul; 246(1):35-43. PubMed ID: 10447223
[TBL] [Abstract][Full Text] [Related]
14. The decrease of mean platelet volume after extracorporeal LDL-cholesterol elimination.
Blaha M; Kostal M; Lanska M; Blaha V; Foralova I; Filip S; Kubisova M; Maly J
Atheroscler Suppl; 2013 Jan; 14(1):77-81. PubMed ID: 23357146
[TBL] [Abstract][Full Text] [Related]
15. Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis.
McGowan MP
J Clin Lipidol; 2013; 7(3 Suppl):S21-6. PubMed ID: 23642325
[TBL] [Abstract][Full Text] [Related]
16. [LDL-apheresis in the treatment familial hypercholesterolemia].
Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P; Sobotka L
Vnitr Lek; 2014 Nov; 60(11):970-6. PubMed ID: 25600044
[TBL] [Abstract][Full Text] [Related]
17. Apheresis-inducible cytokine pattern change in children with homozygous familial hypercholesterolemia.
Küçükçongar A; Yenicesu I; Tümer L; Kasapkara CS; Ezgü FS; Paşaoğlu O; Demirtaş C; Celik B; Dilsiz G; Hasanoğlu A
Transfus Apher Sci; 2013 Jun; 48(3):391-6. PubMed ID: 23651865
[TBL] [Abstract][Full Text] [Related]
18. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.
Lee WP; Datta BN; Ong BB; Rees A; Halcox J
Am J Cardiovasc Drugs; 2011 Dec; 11(6):363-70. PubMed ID: 22149315
[TBL] [Abstract][Full Text] [Related]
19. Treatment of severe hypercholesterolemia by LDL-apheresis: cholesterol-lowering effect and clinical evaluation.
Saito Y; Shinomiya M; Shirai K; Yoshida S
Beitr Infusionsther; 1988; 23():160-71. PubMed ID: 2484772
[No Abstract] [Full Text] [Related]
20. Extracorporeal LDL-cholesterol elimination in the treatment of severe familial hypercholesterolemia.
Bláha M
Acta Medica (Hradec Kralove); 2003; 46(1):3-7. PubMed ID: 12747532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
